The Development of Novel Cancer Immunotherapies and Target Antigens
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (1 January 2025) | Viewed by 2469
Special Issue Editors
Interests: immune–tumor connection for the development of new therapies against brain tumor
Interests: development of novel immunotherapy approaches for treating gliomas and brain metastasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A wide variety of solid tumors still lack an effective therapy. Unfortunately, complete surgical resection often fails to completely eliminate the tumor, leading to the recurrence of cancer and resistance to current therapies. This Special Issue aims to address new immunotherapy strategies along with a description of the immunological microenvironment of tumors, which are difficult to manage clinically. Advances in the design of new strategies against cancer such as immunotherapy, neoantigen vaccines and novel immunomodulators will be evaluated. Furthermore, new immunotherapy strategies may be key to improving current immune checkpoint blockade (ICB) therapies to allow for overcoming the barriers intrinsic to the tumor microenvironment and rethinking the next steps in the evolution of cancer immunotherapy.
Dr. Ricardo Gargini
Dr. Marina I. Garin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- immune checkpoint blockade, ICB
- tumor microenvironment
- immunomodulators
- new immune checkpoint molecules
- cancer vaccines
- novel vaccine platforms
- cell-based vaccines
- virus-based vaccines
- peptide-based vaccines
- nucleic-acid-based vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
